Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
IRONWOOD PHARMACEUTICALS INC (IRWD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS U.S. Net Sales and Ironwood Revenue Guidance"
06/30/2023 8-K Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-B...
Docs: "Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares BOSTON and BASEL, Switzerland – June 29, 2023 – Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, and VectivBio Holding AG , a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio for $17.00 per share in cash . The Depositary for the Tender Offer has advised Ironwood and VectivBio that at the end of the offering period, 59,287,753 Shares had been tendered and not withdrawn pursuant to the Tender Offer and it has received commitments to tender 2,007,310 additional Shares under the guaran..."
05/04/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance",
"Ironwood Pharmaceuticals: A profitable, GI-focused healthcare company3 Our Vision is to be the Leading U.S. GI Healthcare Company​Launched LINZESS in 2012, which today is a blockbuster brand and the #1 prescribed branded treatment in the U.S. for adults with IBS-C or CIC​1 Led by an experienced team with deep GI knowledge, business development savvy, and financial strength underpinned by a strong commitment to patients​•Maximize LINZESS​•Strengthen and Progress Innovative GI Portfolio•Deliver Sustained Profits and Generate Cash Flow​​Proven SuccessDifferentiated GI Capabilities​Focused Priorities 1IQVIA Monthly National Prescription Audit, November 2022."
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/17/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021"
01/10/2022 8-K Investor presentation
Docs: "Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance",
"Leading in GI through Growth and Innovation J.P. Morgan Healthcare Conference January 12, 2022 PRESENTED BY Tom McCourt, CEO Ironwood Pharmaceuticals Exhibit 99.1"
12/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "IRONWOOD PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE AGREEMENT"
11/04/2021 8-K Quarterly results
Docs: "Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update"
08/05/2021 8-K Quarterly results
07/22/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/07/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
02/08/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/03/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors"
11/05/2020 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance",
"Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors"
09/29/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
06/08/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/06/2020 8-K Quarterly results
04/21/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/16/2020 8-K Quarterly results
02/13/2020 8-K Quarterly results
01/13/2020 8-K Investor presentation
Docs: "J.P. Morgan 38"
10/31/2019 8-K Quarterly results
09/18/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO IRONWOOD PHARMACEUTICALS, INC. IF PUBLICLY DISCLOSED.",
"Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® Collaboration in China"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy